Literature DB >> 7908803

Potential pitfalls on the road to an effective HIV vaccine.

D H Schwartz1.   

Abstract

Experimental vaccines for AIDS prophylaxis are being tested in larger and higher-risk populations. Here, David Schwartz, an advocate of HIV-vaccine research and development, highlights some of the concerns that have been voiced about this strategy and presents a simple mathematical model that considers the drawbacks to vaccine-induced expansion of HIV-specific CD4+ T cells.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7908803     DOI： 10.1016/0167-5699(94)90133-3

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


  6 in total

1.  Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope.

Authors:  J Richardson; A Moraillon; S Baud; A M Cuisinier; P Sonigo; G Pancino
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

2.  Differing T-cell requirements for recombinant retrovirus vaccines.

Authors:  K J Hasenkrug; D M Brooks; J Nishio; B Chesebro
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

3.  Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein.

Authors:  Silvija I Staprans; Ashley P Barry; Guido Silvestri; Jeffrey T Safrit; Natalia Kozyr; Beth Sumpter; Hanh Nguyen; Harold McClure; David Montefiori; Jeffrey I Cohen; Mark B Feinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

Review 4.  Murine AIDS: a model for the human disease or a distinct entity?

Authors:  R K Cunnigham; H R Thacore; P Zhou; R Terzian; S Nakeeb; M B Zaleski
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

Review 5.  Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development.

Authors:  Julie Bigay; Roger Le Grand; Frédéric Martinon; Pauline Maisonnasse
Journal:  Front Microbiol       Date:  2022-08-10       Impact factor: 6.064

Review 6.  Vaccine-induced enhancement of viral infections.

Authors:  W Huisman; B E E Martina; G F Rimmelzwaan; R A Gruters; A D M E Osterhaus
Journal:  Vaccine       Date:  2008-11-18       Impact factor: 3.641
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.